[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100495261":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":23,"locations":29,"responsibleParty":47,"collaborators":22,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":22,"eligibilityCriteria":55,"healthyVolunteers":52,"sex":56,"minAge":57,"maxAge":22,"enrollmentInfo":58,"targetDuration":22,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":22,"overallStatus":67,"whyStopped":22,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Northwestern University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CTCL participants","EXPERIMENTAL","Visits will include screening, pre-treatment (week 0), weeks 4 and 8.",[13],"Combination Product: APR-TD011 (RLF-TD011)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"COMBINATION_PRODUCT","APR-TD011 (RLF-TD011)","APR-TD011 (RLF-TD011) wound cleansing spray (drug\u002Fdevice combination product with a 510k clearance that is commercially marketed in the US for use by or on the order of a physician.",[9],[21],"Nexodyn AOS",null,[24],{"name":25,"role":26,"phone":27,"phoneExt":22,"email":28},"Dermatology CTU","CONTACT","312-503-5944","NUderm-research@northwestern.edu",[30],{"facility":25,"status":22,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Chicago","Illinois","60611","United States","US",{"type":37,"coordinates":38},"Point",[39,40],-87.65005,41.85003,{"lat":40,"lon":39},[43,44],{"name":25,"role":26,"phone":27,"phoneExt":22,"email":28},{"name":45,"role":46,"phone":22,"phoneExt":22,"email":22},"Alan Zhou","PRINCIPAL_INVESTIGATOR",{"type":46,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"Xiaolong (Alan) Zhou","Principal Investigator","100495261","early-phase-1-characterization-of-the-microbiome-in-cutaneous-t-cell-lymphoma-skin-lesions-before-and-after-use-of-apr-td011-rlf-td011-spray-solution-100495261",false,"NCT05728879","Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution","Inclusion Criteria:\n\n* Adults with early-stage mycosis fungoides (stages IA-IB)\n* At least two target lesions that have been present for at least 3 weeks and is at least 10 cm2 , so that at least one lesion may be allocated to each of the treatment regimes\n* Target lesion with swab that is culture positive for staphylococcus aureus, but not to an extent that would require systemic antibiotics\n* Agree to avoid washing or using a topical application at the target lesion starting the night before each scheduled study visit.\n* Agree for the duration of study participation to avoid using dilute bleach or vinegar baths, or other antiseptic use, at the target lesion from screening throughout the study.\n\nExclusion Criteria:\n\n* Patients currently or recently (within past 4 weeks) on topical or systemic antibiotics adults unable to provide informed consent, (infants, children, teenagers, pregnant women, prisoners and other vulnerable populations.","ALL","18 Years",{"count":59,"type":60},30,"ESTIMATED","INTERVENTIONAL",[63],"EARLY_PHASE1","This open-label, pilot study will evaluate the tolerance and change in the microbiome from the use of APR-TD011 ((RLF-TD011) wound cleansing spray for the treatment of CTCL skin lesions.",[66],"Cutaneous T Cell Lymphoma","NOT_YET_RECRUITING","2026-04-27",{"date":70,"type":71},"2026-05-01","ACTUAL",{"date":73,"type":60},"2027-01",{"date":75,"type":60},"2028-12",{"name":5,"class":6},1]